Entry Detail


General Information

Database ID:exR0093732
RNA Name:hsa-miR-3917
RNA Type:miRNA
Chromosome:chr1
Starnd:-
Coordinate:
Start Site(bp):25906384End Site(bp):25906403
External Links:hsa-miR-3917



Disease Information

Disease Name:Benign Ovarian Disease
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D010049
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Ovarian Diseases//Disease, Ovarian//Diseases, Ovarian//Ovarian Disease



Expression Detail

GEO ID:GSE106817
Description:Integrated extracellular microRNA profiling for ovarian cancer screening
Experimental Design:Cancer vs Control
Case Disease Type:Benign Ovarian Disease
Case Disease SubType:NA
Case Sample:Benign Ovarian Disease
Control Sample:Non-Cancer
Number of Case:29
Number of Control:2759
Number of Samples:2788





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
BCL2L1
chr20
31664452
31723989
-
PTMS
chr12
6765516
6770952
+
STMN1
chr1
25884181
25906991
-
C1orf56
chr1
151047751
151051986
+
PRKAB2
chr1
147155106
147172550
-
RPLP1
chr15
69452814
69456205
+
miRNA targets:NA
circRNA targets:NA
lncRNA targets:NA
Display:



Experiment Detail

GEO ID:GSE106817
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21263
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2535
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
RNA library preparation protocol:miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.



Reference

PMID:30333487
Title:Integrated extracellular microRNA profiling for ovarian cancer screening
Author:Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T
Journal:Nat Commun. 2018 Oct 17;9(1):4319.
Description:to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.